Moderna MRNA Stock Price, News & Analysis
The first mRNA mpox vaccine to be pitted against licensed vaccines beat its rivals by easing symptoms and potentially cutting transmission, according to new research published Tuesday, a coup for manu…
Key Data
The 13 analysts with 12-month price forecasts for Moderna stock have an average target of 127, with a low estimate of 80 and a high estimate of 179. The average target predicts an increase of 74.24% from the current stock price of 72.89. However, Moderna is developing a robust pipeline that could propel the company for the foreseeable future. Is that pipeline strong enough to warrant buying the stock now, or should investors sit on the sidelines and wait?
The Schall Law Firm Encourages Investors To Join A Case For Securities Fraud Against Moderna Inc
The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. According to 14 analysts, the average rating for MRNA stock is “Buy.” The 12-month stock price forecast is $127.0, which is an increase of 74.24% from the latest price. Moderna is not the only company working on mRNA, but it is the company’s focus, and therefore it can put all its resources toward that technology.
Analyst’s Opinion
Since then, MRNA shares have decreased by 26.7% and is now trading at $72.89. The launch of the RSV vaccine is already being planned for by the company, which believes there is a $10 billion global market for this drug. In 2023, other companies sold approximately $2.3 billion in RSV vaccines, demonstrating the opportunity Moderna has in this market. Before the COVID-19 pandemic, most investors likely hadn’t heard of Moderna (MRNA -0.75%).
Stock Price Forecast
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Approval follows recommendation from global public health bodies to develop JN.1 COVID-19 vaccines At present, the JN.1 group of subvariants remain dominant in the UK The updated vaccine will be avail… Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.
© 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes what is the tweezer candlestick formation or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec…
Moderna is working in other areas as well, including respiratory vaccines, oncology therapeutics, and rare disease therapeutics. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. The average analyst rating for Moderna stock from 14 stock analysts is “Buy”. This means that analysts believe this stock is likely to outperform the market over the next twelve months.
If Moderna can replicate its COVID-19 success with other respiratory viruses like the flu and RSV, there’s a case to be made that shareholders will be rewarded over time. Further down the road are therapeutics for cancer and other diseases that could be additional catalysts for growth. As of this writing, the only commercially available product Moderna has is its COVID-19 vaccine. While this revenue stream has slowed drastically, it should continue into the foreseeable future.
There’s no doubt that the success of the COVID-19 vaccine was proof that mRNA technology is a viable path to pursue for Moderna, which took a lot of the risk out of an investment in the company. That said, it’s worth remembering that this is a very difficult and capital-intensive business, with binary outcomes for the drugs that take millions of dollars to develop. Moderna (MRNA) raised $499 million in an initial public offering on Friday, December 7th 2018. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers. New campaign aims to inform and educate the public about the ongoing risks of COVID-19 and the impact the virus continues to have on day-to-day life Updated vaccines targeting KP.2 variant have been a… Growth stocks offer a lot of bang for your buck, and we’ve got the next upcoming superstars to strongly consider for your portfolio.
Beyond 2025, the company is projecting that several more products will come to market, pending the appropriate regulatory approvals. Moderna approaches the development of vaccines and therapeutics using Messenger a foreign bond issue is a one denominated in a particular currency but sold to RNA (mRNA) technology. Put very simply, a vaccine utilizing mRNA technology teaches the body to make its own medicine.
- At the end of 2019, it was a relatively small biotech company with only collaboration and grant revenue and no commercially available products.
- This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
- Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases.
- The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature’s DNA to other parts of the body.
- Moderna is not the only company working on mRNA, but it is the company’s focus, and therefore it can put all its resources toward that technology.
This is different than traditional vaccines where a harmless version of a virus or bacteria is used to trigger an immune response. Moderna had been working on this technology for nearly a decade before the pandemic broke out, putting the company in a position to get a vaccine to market very quickly. Nearly four years later, the company is in a european pause on astrazeneca vaccine sends stock lower curious spot as it still has only one commercially available product. As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases. Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances.
Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat’s FREE daily newsletter. Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Moderna, Inc.’s combination flu and COVID-19 vaccine, mRNA-1083, showed strong Phase 3 results in adults over 50. Pfizer/BioNTech’s combination vaccine faced setbacks, giving Moderna a potential advan… Amid mounting concerns about the spread of mpox, an experimental vaccine from Moderna may be poised to offer additional protection beyond currently available vaccines, research published Wednesday sho…
The company will develop updated versions as the virus continues to change over time. What is important for the future of the business, and for current and potential investors, is the pipeline of future products. For investors who make Moderna a reasonably sized part of a diversified portfolio, I think the stock is a buy today. As Moderna brings more products to the market, there will be additional opportunities to add to the position over time. Over this year and 2025, Moderna expects to have more products come to market. In addition to the updated versions of the COVID vaccine, Moderna expects approval of a flu/COVID combination vaccine, as well as a vaccine for Respiratory Syncytial Virus (RSV).